Somatropin Recombinant Patent Expiration

1. Genotropin Preservative Free patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5501673 PHARMACIA AND UPJOHN Injection cartridge
Apr, 2013

(11 years ago)

US5435076 PHARMACIA AND UPJOHN Injection device
Apr, 2013

(11 years ago)

US5716338 PHARMACIA AND UPJOHN Dual-chamber type injection cartridge with bypass connection
Feb, 2015

(9 years ago)

US6152897 PHARMACIA AND UPJOHN Syringe
Nov, 2018

(5 years ago)




Market Authorisation Date: 23 October, 1996

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

GENOTROPIN PRESERVATIVE FREE family patents

Family Patents

2. Norditropin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5633352 NOVO NORDISK INC Biosynthetic human growth hormone
May, 2014

(10 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Norditropin Flexpro patent expiration

NORDITROPIN FLEXPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US6716198 NOVO NORDISK INC Injection device
Jun, 2021

(3 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(1 year, 15 days ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month ago)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 3 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 6 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 6 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 6 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 6 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 6 months from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Market Authorisation Date: 23 January, 2015

Treatment: Treatment of disorders responsive to growth hormone

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

4. Norditropin Nordiflex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6235004 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN NORDIFLEX family patents

Family Patents

5. Nutropin Aq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763394 GENENTECH Human growth hormone aqueous formulation
Jun, 2015

(9 years ago)




Market Authorisation Date: 03 January, 2008

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NUTROPIN AQ family patents

Family Patents

6. Nutropin Aq Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763394 GENENTECH Human growth hormone aqueous formulation
Jun, 2015

(9 years ago)




Market Authorisation Date: 03 January, 2008

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NUTROPIN AQ PEN family patents

Family Patents

7. Nutropin Depot patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6051259 GENENTECH Composition for sustained release of human growth hormone
Dec, 2012

(11 years ago)

US5656297 GENENTECH Modulated release from biocompatible polymers
Jul, 2014

(9 years ago)

US5654010 GENENTECH Composition for sustained release of human growth hormone
Aug, 2014

(9 years ago)




Market Authorisation Date: 22 December, 1999

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE

More Information on Dosage

NUTROPIN DEPOT family patents

Family Patents

8. Saizen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5898030 EMD SERONO hGH containing pharmaceutical compositions
Apr, 2016

(8 years ago)




Market Authorisation Date: 16 January, 2007

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

SAIZEN family patents

Family Patents

9. Serostim patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5898030 EMD SERONO hGH containing pharmaceutical compositions
Apr, 2016

(8 years ago)




Market Authorisation Date: 25 July, 1997

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

SEROSTIM family patents

Family Patents

10. Zorbtive patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5898030 EMD SERONO hGH containing pharmaceutical compositions
Apr, 2016

(8 years ago)




Market Authorisation Date: 01 December, 2003

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

ZORBTIVE family patents

Family Patents